On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
REGULATORY
Panel Backs RSV Antibodies for Japan’s Routine Immunization Program
A Japanese health ministry panel concluded on October 22 that using two anti-RSV antibody products under the national immunization program (NIP) is scientifically sound, paving the way for their potential inclusion in routine RSV prevention for infants. The Health Sciences…
To read the full story
Related Article
- MSD Set to Match Beyfortus Price for RSV Antibody Enflonsia if Added to NIP
November 12, 2026
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
July 23, 2026
- Japan Eyes Early FY2027 Rollout of RSV Antibodies under NIP: Minister
July 21, 2026
- MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
May 21, 2026
REGULATORY
- Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
November 12, 2026
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- Japan to List Eylea Biosimilars from SamChunDang, Celltrion on Nov. 13
November 12, 2026
- PMDA Sees Little Need for Separate Dosage Form Category for Mini-Tablets
November 11, 2026
- Japan Eyes Nationwide Probe into Wartime Drug Trials on Leprosy Patients
November 11, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…